🧬 Endocrinology Update: Acromegaly Heart Breakthrough, AI in Diabetes, New Biosimilars and More
From innovative cardiac procedures in rare endocrine disorders to AI-driven diabetes management and game-changing biosimilar approvals—this week’s endocrinology news is packed with clinical insights and pharma headlines that matter.
📌 In This Episode:
🫀 Cardiac Innovation in Acromegaly: A 79-year-old patient undergoes a complex yet successful heart procedure.
💊 ESTEVE Expands in Rare Cancers: Acquires Caprelsa® for medullary thyroid cancer treatment in over 50 countries.
🌏 Biocon’s 100M Milestone: Integrated insulin production reaches new heights in Malaysia.
💪 Denosumab Biosimilars Approved: Biocon and mAbxience receive EU nod for multiple bone health therapies.
🇰🇷 Samsung Bioepis Launch: Affordable Prolia® biosimilar hits the market in South Korea.
🦴 Eladynos Approved in Scotland: A major win for high-fracture-risk osteoporosis patients.
🧠 AI-Powered Bone Risk Tool: Medimaps launches TBS Osteo Advanced in Europe.
🤖 AI Rivals Doctors in Diabetes Management: iNCDSS system matches human-led insulin decisions.
💉 IcoSema Trial Results: Superior HbA1c reduction of 1.55 percent and weight loss of 5.6 kg in T2D.
🤰 Pregnancy-Linked Type 1 Diabetes: New research reveals clinical and genetic predictors.
🧪 TZIELD® Real-World Study: Sanofi releases long-term safety insights for Stage 2 Type 1 Diabetes.
💊 Eli Lilly’s Orforglipron Advances: Promising oral GLP-1 shows Phase 3 efficacy in T2D.
🔬 Pregnancy Triggers for T1D: Study reveals immunosuppressive and genetic factors post-gestation.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on diabetes, osteoporosis, thyroid cancer, and more.
#Endocrinology #DiabetesCare #Osteoporosis #AIinHealthcare #Biosimilars #Cardiology #MedTech #EndocrineDisorders #RareDisease #Type1Diabetes #Type2Diabetes #PharmaNews #HealthcareInnovation